ALL — The Allstate Corporation

Despite an excellent Q2 2026, the tape has cooled — price fell 1.6% to $257.62 on 2026-08-27 and RSI sits at 49.68. Sell-side is mixed (18 buy, 22 hold, 4 sell), and July's $682M pre-tax catastrophe losses remind investors that underwriting results are lumpy. The market is constructive but not chasing.

Clear acceleration. Revenue has climbed from $14.3B in Q3 2023 to $18.6B in Q2 2026; operating income swung from a $21M loss in Q3 2023 to $4.24B in Q2 2026. Q2 2026 YoY revenue rose 11.8% and EPS jumped to $12.51 from $7.76, with the combined ratio improving 4.5 points to 86.6. This is an inflection, not a one-off quarter, though P&C earnings remain lumpy — Q1 2025's weak $2.11 EPS shows how much quarterly noise can occur.

As of 2026-08-27 the stock is not as cheap as the headline 5.08x trailing P/E suggests, because TTM EPS of $51.99 is cyclically strong. On consensus forward EPS of $34.93, ALL trades at about 7.38x, below its 5-year average P/E of 7.77, but P/S of 0.96 is above the 5-year average of 0.74. Net-net: fairly valued to modestly attractive on forward earnings, consistent with the valuation_context label of 'Neutral vs. its own history.'

The market is pricing in a partial normalization from $51.99 trailing EPS toward roughly $34.93 forward EPS. If Q2 2026's annualized run-rate persisted, $257.62 would be a deep-value ~5x earnings; but an 86.6 combined ratio is unusually good and consensus expects it to fade. So the stock is paying a fair multiple for a high-quality franchise, not pricing in a turnaround or a collapse.

As of 2026-08-27: price $257.62, RSI 49.68 (neutral), -1.49% vs 20-day, +1.91% vs 50-day, +16.98% vs 200-day. The stock remains in an uptrend above its 200-day but is consolidating below the $277.22 high. No oversold entry signal; a pullback toward the 50-day would offer better risk/reward.

• Elevated long-term Treasury yields are boosting net investment income, up 33.8% YoY to $1.0B in Q2 2026.
• Stabilizing auto-repair inflation and implemented homeowners rate hikes are supporting underwriting margins.
• Weather volatility remains a persistent headwind — July 2026 alone saw $682M pre-tax catastrophe losses, mostly wind/hail.
• Reinsurance availability and pricing affect how much catastrophe shock Allstate can absorb in a given quarter.
• Capital-return environment: $1.3B returned in Q2, including $1B buybacks, supports EPS and valuation.

• Q3 2026 earnings, expected early November 2026 — can the combined ratio stay below 87 into heavier storm season?
• Monthly catastrophe-loss disclosures will drive near-term sentiment.
• Execution on the remaining ~$2.6B buyback authorization supports per-share value.
• Further rate hikes and AI-driven claims efficiency could extend underwriting outperformance.

• Above-normal hurricane or wildfire activity could produce large catastrophe losses beyond reinsurance.
• Re-acceleration of auto/property claims inflation would pressure the combined ratio.
• Interest-rate and investment-market swings could hurt investment income and book value.
• Regulatory or competitive pushback on rate increases could slow the growth engine.
• Mean-reversion risk: forward EPS estimates (~$34.93) are well below trailing EPS ($51.99), so if underwriting normalizes, the stock could de-rate.

Allstate is a well-run P&C compounder with accelerating revenue, best-in-class underwriting (86.6 combined ratio), strong investment income growth, and solid capital return. At roughly 7.4x forward EPS it is a reasonable long-term buy, though the run-up and mixed analyst consensus argue for measured entry rather than chasing strength.

Fair value = 8.0x consensus forward EPS of $34.93 = $279.44. The 8.0 multiple is a slight premium to Allstate's 7.77 historical average P/E, justified by 20.8% ROIC, the 86.6 combined ratio, and 33.8% investment income growth, but capped by P&C cyclicality and normalized-earnings risk.